1 / 37

COST Action IS1002 Modernet Annet Lenderink 19 March 2012, ICOH congress 2012

Modernet , a network for development of new techniques for measuring trends in occupational and work-related diseases and tracing new and emerging risks. COST Action IS1002 Modernet Annet Lenderink 19 March 2012, ICOH congress 2012. Overview of this presentation. Introduce myself

kachina-baker
Download Presentation

COST Action IS1002 Modernet Annet Lenderink 19 March 2012, ICOH congress 2012

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Modernet, a network for development of new techniques for measuring trends in occupational and work-related diseases and tracing new and emerging risks COST Action IS1002 Modernet Annet Lenderink 19 March 2012, ICOH congress 2012

  2. Overview of this presentation • Introduce myself • Introduce Modernet en COST Action IS1002 • OSH vigilance and signal management • Current activities

  3. Annet Lenderink • Occupational physician 1984-1996 • Freelance journalist/webmaster 1996-2005 • Coordinator Knowledge Dissemination Netherlands Center for Occupational Diseases (NCOD) 2005-2009 • Physician-researcher NCOD since July 2009 • Research projects on occupational diseases

  4. Netherlands Tulips and wind mills and orange coloured sports

  5. What is Modernet? Like us on Facebook! • Network of institutes and people dedicated to research in Occupational Diseases • Started small, but with great ambitions for international collaboration • Funded by EU for meetings to exchange knowledge and expertise

  6. Background (1) • High morbidity and mortality by Occupational Diseases (ODs) • High economic costs • Changing working conditions may cause new ODs • Nanotechnology • Introduction of new substances • Global economy • EU Community Strategy on health and safety 2007-2012: Ongoing reduction of occupational diseases is a prime objective

  7. Background (2) • Present systems for monitoring and recognition of new OH risks are inadequate • Need for: • reliable and comparable systems for monitoring ODs • Better methods for identifying and assessing new risks in a changing work environment • international collaboration (intelligence network)

  8. Modernet goals • Improvement of quality of data on ODs • New and smarter techniques for early detection of trends of occupational diseases • Early detection of new OH risks • Rapid exchange of research knowledge with the use of (new) internet techniques such as social media • Enhance the opportunities for appropriate preventive action

  9. Modernet, brief history (1) • Mutual meetings between institutes on OD registries in Manchester and Amsterdam between 2004 and 2006 • Invitational conferences (Amsterdam, 2007 and 2008), mainly on tracing new OH risks with participants from NL, F, UK, I, Fi, Cz • Meetings of Modernet consortium in Paris (2009) and Milan (2010) , 1 day on methodology, 1 day on new OH risks with participants from same countries

  10. COST Modernet, brief history • Funding granted from EU in summer 2010 • Start of COST Action IS1002 Modernet, November 2010 • More countries participating up till 15 now • International congress “Tracing New Occupational Diseases” in Amsterdam, April 2011 • Meetings In Amsterdam and Manchester in 2011 • Next COST Action meeting in Leuven, Belgium, June 2012

  11. Participants of Modernet Iceland Ireland Norway Finland Germany UK Belgium Netherlands Spain France CzechRepublic Portugal** Italy FYROM Croatia Australia Albania

  12. Working groups • WG1 Quality of data: improvement of quality of data collection in occupational diseases (WG-leader: Prof. Stefano Mattioli) • WG2 Trends Analysis: New techniques for analysis of trends in occupational diseases (WG-leaders: Dr. Roseanne McNamee and Prof. Raymond Agius) • WG3 Tracing new risks: New techniques for tracing newly occurring occupational diseases (WG-leader: Dr. Vincent Bonneterre) • WG4 Dissemination: dissemination and implementation of new knowledge on occupational diseases (WG-leaders: Dr. Claudio Colosio)

  13. Tracing new occupational diseases Work groups on new and emerging respiratory, skin, musculoskeletal, psychosocial, neurological and reproductive problems Key note speakers on methodology and policy Participation through either oral presentation or poster Also half term meeting ICOH SCOM 100+ participants

  14. Diagnosis of ODs

  15. Occupational Disease (OD)The 5-step roadmap • Diagnose the disease or disorder • Is there evidence for a relation between disease and the occupation, work situation or work exposure? • Determine/measure the exposure to risk/work factors • Determine/measure the exposure to other factors • Weigh the information, decide and report to the patient/worker, the employer and to the registry of NCvB (Netherlands Center for Occupational Diseases)

  16. But whatabout new occupationaldiseases? Louis Pasteur: “Chance favours only the prepared mind…”

  17. New risks or diseases • From symptoms and signs no disease can be diagnosed • No certainty on possible causal factors • Hardly any research reported • No plausible biological model to explain the relation between exposure and disease

  18. Emerging OSH risks “New” • Previously unknown and caused by new processes, new technologies, new types of workplace, or social or organizational change; • Long-standing issue, newly considered as a risk due to a change in social or public perceptions (e.g. stress, bullying); • New scientific knowledge allows a long-standing issue to be identified as a risk

  19. Johan Cruijff:"You will only see it, if you understand it"

  20. Anticipation on new OH risks (1) Europe / worldwide: main focus is on risk assessment, by means of Risk analyses Follow-up of risk groups REACH initiative: Registration, Evaluation, Authorization and Restriction of Chemical substances Expert Forecasts of Risk Observatory Bilbao 20

  21. Anticipation on new OH risks (2) Complementary to risk assessment is the “Disease first” approach Use of disease as a starting point for analysis Disease tracking by for example by Trend analyses (useful with high prevalence, low occupational Attributive Risk) Spontaneous reporting (useful with low prevalence, high occupational Attributive Risk) 21

  22. Detect new health risks in work Learn from the detection of adverse drug reactions Pharmacovigilance  OHS vigilance

  23. OSH vigilance goals: Aims to detect, assess and prevent adverse effects of work or any other possible work-related problems Detect unexpected, unknown adverse effects of work Detect increases in frequency of adverse work effects Detect risk factors (i.e. risk groups, co-morbidity) and mechanisms Quantitative evaluation of adverse work effects Interpretation of data and disseminating knowledge

  24. It’s all about signal management Signal generation and detection Signal strengthening Signal validation From signal to action

  25. A signal is… …a hypothesis about a possible relation between exposure and a health problem, supported by data and arguments, that needs to be tested

  26. Signal generation and detection Spontaneous reports of disease-exposure links by OPs, GPs or medical specialists Spontaneous reports by workers Periodic literature screening Data mining in databases Linking databases Active detection of effects on health Secondary analysis of patient data in other databases

  27. Bottum line: an urgent need for vigilant physicians ‘Your case might be the first one!’

  28. Signalstrengthening (1) Preliminary evaluation of the relevance of the signal: Early warning Social perspective Interesting signal from a scientific or educational perspective

  29. Signalstrengthening (2) Using 5-step roadmap 1. Determine the health damage 2. Determine the relationship with work 3. Determine the exposure 4. Are other explanations possible? 5. Finally, a conclusion must be reached and an associated report issued

  30. Signalvalidation (1) through (epidemiological) research: The strength of the signal: for instancedoubling of the risk of developing disease when exposed to the risk (RR>2) Consistency of the data: different studies point in the same direction Specificity: the specific risk concerned is associated with a clearly defined disease Sequence: first exposure, then disease development

  31. Signalvalidation (2) Biologic gradient, or dose-effect relation: higher exposure leads to greater risk of disease Biologic plausibility: does the clinical picture match up with what is known about how the disease develops? Analogy: evidence of corresponding experiences with related material Nature and quality of the data: objective observations, precise documentation

  32. Fromsignalto action Communication with parties directly involved Communication with external parties Initiation of further research When and where necessary: amending guidelines, protocols, legislation and regulations

  33. Research by COST Modernet participants (1) Improvement of data on occupational diseases, examples • By use of more sources (triangulation): • GP surveillance (Hussey et al, 2008) • Specialist physicians surveillance (McNamee et al, 2008; Pal et al, 2009) • Improvement of physician participation (Spreeuwers et al, 2008, Lenderink et al, 2009) • Review on the validity of self-report to assess work-related diseases (Lenderink et al, 2011) • Audit tool for the quality of registries of occupational diseases (Spreeuwers et al, 2009) • Joined proposal for Cochrane review on how to reduce underreporting of occupational diseases

  34. Research by COST Modernet participants (2) Analysis of trends, examples of techniques: • MLM (Multi Level Model) - THOR, McNamee et al. • ZINB (zero inflation negative binomial model) - RNV3P, Paris et Ngatchou • ACMMT (Adjusted Count Models for Measuring Trends - RNV3P • ILRMMT (Internal logistic regression for measuring trends - RNV3P, Paris et al.; Bensefa et al. Analysis of trends, examples of research into impact of prevention • Directives etc. regarding Chromium VI (Stocks et al -UK) • Reduction of exposure to latex allergen in gloves (Turner et al -UK) • Use of glutaraldehyde (In preparation: Stocks et al –UK) • CTE- Chronictoxicencephalopathy in the Netherlands (van der Laan)

  35. Research by COST Modernet participants (3) New methods to trace newly occurring occupational diseases • Preparation for clinical watch system (sentinel approach) • Discussion on examples of new associations of exposure and disease discussed within the network (congress “Tracing new Occupational diseases” book of abstracts on www.costmodernet.org) • Concerning Data Mining Methods • The UK group has been working on QSARS and asthma • Comparison of pharmacovigilance methods : article to be published in SH@W in early 2012 • French and UK groups start working on the use of GIS (Geographical Information Systems): mobility project (IEF) and a PhD thesis 2012-2015 (Grenoble / Paris, France).

  36. Currentactivitieswithin COST Modernet • Dissemination: • Website • Facebook • LinkedIn

  37. Thank you Gracias Time for questions a.f.lenderink@amc.nl

More Related